{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"Progression free survival is defined as the percentage of patients with stable disease or no death. Stable disease is defined as less than a partial response but is not progressive disease. Partial Response (PR)-At least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses as determined byFDG-PET for CT scan. No increase should be observed in the size of other nodes, liver, or spleen. Patients who achieve a CR by the above criteria, but who have persistent morphologic bone marrow involvement will be considered partial responders. When the bone marrow was involved before therapy and a clinical CR was achieved, but with no bone marrow assessment after treatment, patients should be considered partial responders.","groups":[{"description":"Doxycycline 200 mg twice daily\n\nDoxycycline","id":"OG000","title":"Doxycycline"}],"paramType":"NUMBER","populationDescription":"Data was collected on all patients who were enrolled.","reportingStatus":"POSTED","timeFrame":"One year","title":"Percentage of Patients With Progression Free Survival","type":"SECONDARY","unitOfMeasure":"percentage of participants"}